Stryker Co. (NYSE:SYK) Shares Sold by Harbour Investment Management LLC

Harbour Investment Management LLC trimmed its holdings in shares of Stryker Co. (NYSE:SYK) by 3.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,630 shares of the medical technology company’s stock after selling 460 shares during the period. Stryker accounts for 2.2% of Harbour Investment Management LLC’s portfolio, making the stock its 11th biggest position. Harbour Investment Management LLC’s holdings in Stryker were worth $4,919,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Chicago Capital LLC raised its holdings in shares of Stryker by 3.1% during the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock worth $70,228,000 after purchasing an additional 5,841 shares during the period. Zhang Financial LLC grew its position in shares of Stryker by 55.0% during the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after acquiring an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA grew its position in shares of Stryker by 5.0% during the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company’s stock worth $10,521,000 after acquiring an additional 1,400 shares during the last quarter. Metis Global Partners LLC grew its position in shares of Stryker by 10.2% during the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock worth $6,064,000 after acquiring an additional 1,561 shares during the last quarter. Finally, US Bancorp DE grew its position in shares of Stryker by 0.5% during the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company’s stock worth $65,829,000 after acquiring an additional 976 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on SYK shares. Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Stifel Nicolaus upped their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research report on Tuesday, March 4th. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, Barclays increased their target price on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Price Performance

SYK stock opened at $369.96 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The firm has a market capitalization of $141.17 billion, a PE ratio of 47.68, a P/E/G ratio of 2.93 and a beta of 0.95. The firm has a 50-day moving average of $383.04 and a two-hundred day moving average of $373.37.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm earned $3.46 earnings per share. On average, analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.